Literature DB >> 26210317

The antidepressant-like activity of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one involves serotonergic 5-HT(1A) and 5-HT(2A/C) receptors activation.

Karolina Pytka1, Maria Walczak2, Agnieszka Kij3, Anna Rapacz4, Agata Siwek5, Grzegorz Kazek4, Adrian Olczyk6, Adam Gałuszka6, Anna Waszkielewicz7, Henryk Marona7, Jacek Sapa4, Barbara Filipek4.   

Abstract

Xanthone derivatives have been shown to posses many biological properties. Some of them act within the central nervous system and show neuroprotective or antidepressant-like properties. Taking this into account we investigated antidepressant-like activity in mice and the possible mechanism of action of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one (HBK-11) - a new xanthone derivative. We demonstrated that HBK-11 produced antidepressant-like effects in the forced swim test and tail suspension test, comparable to that of venlafaxine. The combined treatment with sub-effective doses of HBK-11 and fluoxetine (but not reboxetine or bupropion) significantly reduced the immobility in the forced swim test. Moreover, the antidepressant-like activity of HBK-11 in the aforementioned test was blocked by p-chlorophenylalanine, and significantly reduced by serotonergic 5HT1A receptor antagonist - WAY-1006335 and 5HT2A/C receptor antagonist - ritanserin. As none of the above treatments influenced the spontaneous locomotor activity, it can be concluded that HBK-11 mediates its activity through a serotonergic system, and its antidepressant-like effect involves 5HT1A and 5HT2A/C receptor activation. Furthermore, at antidepressant-like doses HBK-11 did not cause the mice to display locomotor deficits in rotarod or chimney tests. Considering the pharmacokinetic profile, HBK-11 demonstrated rapid absorption after i.p. administration, high clearance value, short terminal half-life, very high volume of distribution and incomplete bioavailability. The compound studied had good penetration into the brain tissue of mice. Since studied xanthone derivative seems to present interesting, untypical mechanism of antidepressant-like action i.e. 5HT2A/C receptor activation, it may have a potential in the treatment of depressive disorders, and surely requires further studies.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-HT(1A) receptor; 5-HT(2) receptor; Antidepressant-like activity; Bioavailability; Distribution in brain; Mass spectrometry

Mesh:

Substances:

Year:  2015        PMID: 26210317     DOI: 10.1016/j.ejphar.2015.07.041

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

2.  Modulation of brain ACE and ACE2 may be a promising protective strategy against cerebral ischemia/reperfusion injury: an experimental trial in rats.

Authors:  Maha Mohammed Abdel-Fattah; Basim Anwar Shehata Messiha; Ahmed Mohamed Mansour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-17       Impact factor: 3.000

3.  HBK-14 and HBK-15 with antidepressant-like and/or memory-enhancing properties increase serotonin levels in the hippocampus after chronic treatment in mice.

Authors:  Karolina Pytka; Katarzyna Gawlik; Dorota Pawlica-Gosiewska; Jadwiga Witalis; Anna Waszkielewicz
Journal:  Metab Brain Dis       Date:  2016-11-25       Impact factor: 3.584

4.  Single Administration of HBK-15-a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist-Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone.

Authors:  Karolina Pytka; Monika Głuch-Lutwin; Magdalena Kotańska; Anna Waszkielewicz; Agnieszka Kij; Maria Walczak
Journal:  Mol Neurobiol       Date:  2017-05-26       Impact factor: 5.590

5.  Antidepressant- and Anxiolytic-Like Effects of New Dual 5-HT₁A and 5-HT₇ Antagonists in Animal Models.

Authors:  Karolina Pytka; Anna Partyka; Magdalena Jastrzębska-Więsek; Agata Siwek; Monika Głuch-Lutwin; Barbara Mordyl; Grzegorz Kazek; Anna Rapacz; Adrian Olczyk; Adam Gałuszka; Marian Błachuta; Anna Waszkielewicz; Henryk Marona; Jacek Sapa; Barbara Filipek; Anna Wesołowska
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

6.  H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice.

Authors:  Magdalena Dudek; Kamil Kuder; Marcin Kołaczkowski; Adrian Olczyk; Elżbieta Żmudzka; Aleksandra Rak; Marek Bednarski; Karolina Pytka; Jacek Sapa; Katarzyna Kieć-Kononowicz
Journal:  Metab Brain Dis       Date:  2016-05-24       Impact factor: 3.584

7.  The antidepressant- and anxiolytic-like activities of new xanthone derivative with piperazine moiety in behavioral tests in mice.

Authors:  Karolina Pytka; Elżbieta Żmudzka; Klaudia Lustyk; Anna Rapacz; Adrian Olczyk; Adam Gałuszka; Anna Waszkielewicz; Henryk Marona; Jacek Sapa; Filipek Barbara
Journal:  Indian J Pharmacol       Date:  2016 May-Jun       Impact factor: 1.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.